Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
Laiyan Zhou, Mai Zhang, Rui Li, et al.
Journal of Cancer Research and Clinical Oncology (2020) Vol. 146, Iss. 12, pp. 3269-3279
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors
Julien Ancel, Valérian Dormoy, Béatrice Nawrocki‐Raby, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 19
Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond?
Jiaming Lei, Jianbao Yang, Cuiyu Bao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
Da Hyun Kang, Chaeuk Chung, Pureum Sun, et al.
Cancer Immunology Immunotherapy (2021) Vol. 71, Iss. 3, pp. 579-588
Open Access | Times Cited: 38
Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs
Jason Chibuk, Andi Flory, Kristina M. Kruglyak, et al.
Frontiers in Veterinary Science (2021) Vol. 8
Open Access | Times Cited: 34
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Marco Russano, Giulia La Cava, Alessio Cortellini, et al.
Current Oncology (2023) Vol. 30, Iss. 2, pp. 2366-2387
Open Access | Times Cited: 16
Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation
Jing Sang, Xin Ye
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Efficacy and safety of immunotherapy in real-world patients with advanced non-small cell lung cancer
Na Yin, Ruihan Yang, Xiangliang Liu, et al.
Cancer Treatment and Research Communications (2025), pp. 100908-100908
Open Access
Multiple pseudoprogressions during ongoing immunotherapy-based treatment of advanced gastric neuroendocrine carcinoma: A case report and review of literature
Yanhua Mou, Juan Zhang, Hui Shen, et al.
World Journal of Gastrointestinal Oncology (2025) Vol. 17, Iss. 3
Closed Access
Delta‐He as a Novel Predictive and Prognostic Biomarker in Patients With NSCLC Treated With PD–1/PD‐L1 Inhibitors
Green Hong, Song‐I Lee, Da Hyun Kang, et al.
Cancer Medicine (2025) Vol. 14, Iss. 7
Open Access
Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer
Julian Goggi, Siddesh V. Hartimath, Tan Yun Xuan, et al.
Molecular Imaging and Biology (2021) Vol. 23, Iss. 5, pp. 714-723
Open Access | Times Cited: 22
Gut Microbiota-Derived PGF2α Fights against Radiation-Induced Lung Toxicity through the MAPK/NF-κB Pathway
Zhiyuan Chen, Huiwen Xiao, Jiali Dong, et al.
Antioxidants (2021) Vol. 11, Iss. 1, pp. 65-65
Open Access | Times Cited: 22
Machine learning guided signal enrichment for ultrasensitive plasma tumor burden monitoring
Adam J. Widman, Minita Shah, Nadia Øgaard, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 13
Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis
Ling Tao, Lianghui Zhang, Rui Peng, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12
Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non–Small Cell Lung Cancer
Xuhe Liao, Meng Liu, Rongfu Wang, et al.
Frontiers in Genetics (2022) Vol. 12
Open Access | Times Cited: 11
A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma
Xuewen Wang, Chengfei Zhao, Dandan Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update
Inga Trulson, Stefan Holdenrieder
Tumor Biology (2023) Vol. 46, Iss. s1, pp. S111-S161
Open Access | Times Cited: 5
Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy
Trie Arni Djunadi, Youjin Oh, Jeeyeon Lee, et al.
Clinical Lung Cancer (2024) Vol. 25, Iss. 4, pp. 365-375.e14
Open Access | Times Cited: 1
CT-Based Peritumoral and Intratumoral Radiomics as Pretreatment Predictors of Atypical Responses to Immune Checkpoint Inhibitor Across Tumor Types: A Preliminary Multicenter Study
Shuai He, Yuqing Feng, Qi Lin, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 10
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice
Joseph Zouein, Fadi G. Haddad, Roland Eid, et al.
Immunotherapy (2021) Vol. 14, Iss. 2, pp. 155-167
Closed Access | Times Cited: 10
Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab
Ryuta Shigefuku, Kyoko Yoshikawa, Mone Tsukimoto, et al.
Internal Medicine (2022) Vol. 62, Iss. 4, pp. 539-543
Open Access | Times Cited: 7
Analysis of diagnostic value of CTC and CTDNA in early lung cancer
Hongwei Yao, Lixin Wen, Ziyan Li, et al.
Cellular and Molecular Biology (2023) Vol. 69, Iss. 6, pp. 57-62
Open Access | Times Cited: 3
Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
Yanping Li, Tianhong Chen, Tian Nie, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 2
Further discussion on the association between desmoglein 2 and tumor size of non-small cell lung cancer
Siyuan Hao, Jiayi Liu, Ma Jia
Journal of Cancer Research and Clinical Oncology (2020) Vol. 147, Iss. 2, pp. 633-635
Closed Access | Times Cited: 5
The Feasibility of Using Biomarkers Derived from Circulating Tumor DNA Sequencing as Predictive Classifiers in Patients with Small-Cell Lung Cancer
Yu Feng, Yutao Liu, Zicheng Yu, et al.
Cancer Research and Treatment (2021) Vol. 54, Iss. 3, pp. 753-766
Open Access | Times Cited: 5
Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy
Trie Arni Djunadi, Youjin Oh, Jeeyeon Lee, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Page 1 - Next Page

Scroll to top